<DOC>
	<DOCNO>NCT01410214</DOCNO>
	<brief_summary>The purpose study assess effect safety erlotinib versus NVB plus cisplatin ( NP ) adjuvant treatment patient stage IIIA NSCLC complete resection EGFR activate mutation explore new treatment strategy subset .</brief_summary>
	<brief_title>Erlotinib Versus Vinorelbine/Cisplatin Adjuvant Treatment Stage IIIA NSCLC Patients With EGFR Mutations</brief_title>
	<detailed_description>The LACE meta-analysis identify four cycle platinum-based program improve II~IIIA stage completely resect NSCLC pt role 5-year survival , treatment-related life threaten toxicity limit use . The EGFR tyrosine kinase inhibitor ( TKI ) may provide dramatic response pt pulmonary adenocarcinoma carry EGFR activate mutation metastatic setting . The aim study investigate efficacy safety erlotinib versus NVB plus cisplatin ( NP ) adjuvant treatment pt stage IIIA NSCLC Complete Resection EGFR activate mutation explore new treatment strategy subset .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Written inform consent provide . Males female age ≥18 year . Chest CT , brain CT MRI , ECT , abdominal doubleneck B , whole body PETCT examination 4 week complete resection . Pathological diagnose nonsmall cell lung cancer . Diagnosed stage IIIA . In 4 week complete resection pt start accept adjuvant therapy study , previously receive antitumor therapy . EGFR activate mutation exon 19 21 KARS ECOG performance status 01 . Life expectancy ≥3 month . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L , Hemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 2.5 x ULN . Adequate renal function : Serum creatinine ≤ 1.25 x ULN , creatinine clearance ≥ 60 ml/min . Able comply require protocol followup procedure , able receive oral medication . Patients must nonpregnant nonlactating.Patients childbearing potential must implement effective method contraception study . All female Patients , except postmenopausal surgically sterilize , must negative prestudy serum urine pregnancy test . . Patients prior exposure agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) . Patients prior chemotherapy therapy systemic antitumour therapy . Patients prior radiotherapy . History another malignancy last 5 year exception following : Cured basal cell carcinoma skin cure situ carcinoma uterine cervix permit . Any evidence confirm tumor recurrence adjuvant treatment . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Any evidence clinically active interstitial lung disease . Eye inflammation eye infection fully treat condition predispose subject . Known human immunodeficiency virus ( HIV ) infection . Known hypersensitivity Tarceva NVB cisplatin . Pregnancy breastfeed woman . ECOG performance status ≥ 2 . Ingredients mixed small cell lung cancer patient Evidence disease , neurological metabolic dysfunction , physical examination laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put subject high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR Mutation Positive</keyword>
	<keyword>complete resection</keyword>
	<keyword>Erlotinib Versus NVB/Cisplatin Adjuvant treatment</keyword>
</DOC>